CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54,516 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01077856
NCT01077856N/ACompleted
CompareCT.gov

GARDASIL™ Vaccine Impact in Population Study

Merck Sharp & Dohme LLC·observational·Posted Mar 1, 2010·Updated Sep 13, 2022

In Brief

An observational study for Human Papillomavirus Infections. Completed, enrolled 54,516 participants.

Detailed Summary

This study will assess the impact of GARDASIL™ human papillomavirus (HPV) vaccine in the general female population by utilizing nationwide registry databases in the participating Nordic countries.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Papillomavirus Infections
Countries--
CollaboratorsDanish Cancer Society, Union for International Cancer Control, Norwegian Institute of Public Health, Karolinska Institutet

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 1, 2010
Enrollment StartMay 29, 2007
Primary CompletionDec 2, 2014
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 16.3 years ago